Central Nervous System (CNS) Therapeutics Strategic Business Report 2025-2030 – Biologics, Gene Therapies, and Small Molecules Converge in Development Pipelines for CNS Disorders – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Central Nervous System Therapeutics Market – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Central Nervous System Therapeutics was valued at US$107 Billion in 2024 and is projected to reach US$156.5 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The global CNS therapeutics market is growing due to increasing disease burden, heightened awareness of mental and neurological health, and the rapid advancement of therapeutic science. Unmet needs across multiple CNS indications, combined with demographic pressures and healthcare digitization, are generating sustained demand for both novel and reformulated therapies. Public and private sector investments in neuroscience research, along with regulatory support for orphan drug development and accelerated pathways, are further incentivizing innovation.

Pharmaceutical companies are expanding pipelines through acquisitions, collaborations, and AI-enabled drug discovery platforms focused on CNS targets. At the same time, patient advocacy, digital care models, and personalized treatment paradigms are shifting the industry toward more holistic, outcomes-driven approaches

As complexity in CNS care deepens and precision treatment becomes more attainable, a defining question shapes the market’s future: can CNS therapeutics continue to evolve through biomarker-guided innovation, cross-disciplinary care models, and scalable delivery platforms – while addressing the dual challenge of clinical uncertainty and global accessibility?

Report Scope

The report analyzes the Central Nervous System Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Drug Class (Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives & Hypnotics, Anti-Depressants, Other Drug Classes); Disease Type (Neurodegenerative Disorders, Mental Health, Neurovascular Diseases, CNS Trauma, CNS Cancer, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Questions Answered:

• How is the Global Central Nervous System Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Central Nervous System Therapeutics market report include:

• AbbVie Inc.
• Allergan plc
• Anavex Life Sciences Corp.
• AstraZeneca plc
• Biogen Inc.
• Bristol Myers Squibb
• Cipla Limited
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Roche Holding AG
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.

Key Attributes

MARKET OVERVIEW

• Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
• World Market Trajectories
• Central Nervous System Therapeutics – Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Rising Prevalence of Alzheimer’s, Parkinson’s, and Epilepsy Fuels Demand for CNS Drug Innovation
• Biologics, Gene Therapies, and Small Molecules Converge in Development Pipelines for CNS Disorders
• Cross-BBB Delivery Technologies and Neurotargeted Carriers Address Long-Standing Bioavailability Barriers
• Psychiatric Disorders Like Depression and Bipolar Drive Growth in Multimodal CNS Treatment Strategies
• Digital Therapeutics and CNS Drug Monitoring Tools Expand Clinical Management Capabilities
• Patient-Centered Outcome Measures Gain Priority in CNS Trial Designs and Payer Decisions
• High Unmet Need in Rare Neurological Conditions Spurs Orphan Drug Development Activity
• Aging Demographics and Lifestyle Shifts Expand CNS Therapeutic Demand Across Regions

For more information about this report visit https://www.researchandmarkets.com/r/onu2xr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900